**Name of Journal:** *World Journal of Stem Cells*

**Manuscript NO:** 82568

**Manuscript Type:** MINIREVIEWS

**Molecular signaling in cancer stem cells of tongue squamous cell carcinoma: Therapeutic implications and challenges**

Joshi P *et al*. Cell signaling in CSCs of tongue carcinoma

Priyanka Joshi, Sanjeev Waghmare

**Priyanka Joshi, Sanjeev Waghmare,** Stem Cell Biology Group, Cancer Research Institute, Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai 410210, India

**Author contributions:** Waghmare S conceptualized the review article; Waghmare S and Joshi P wrote the manuscript.

**Corresponding author: Sanjeev Waghmare, PhD, Senior Scientist,** Stem Cell Biology Group, Cancer Research Institute, Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre, Sector 22, Utsav Chowk-CISF Road, Kharghar, Navi Mumbai 410210, India. swaghmare@actrec.gov.in

**Received:** December 22, 2022

**Revised:** February 21, 2023

**Accepted:** April 7, 2023

**Published online:** May 26, 2023

**Abstract**

Head and neck squamous cell carcinoma is the seventh most common cancer worldwide with high mortality rates. Amongst oral cavity cancers, tongue carcinoma is a very common and aggressive oral cavity carcinoma. Despite the implementation of a multimodality treatment regime including surgical intervention, chemo-radiation as well as targeted therapy, tongue carcinoma shows a poor overall 5-year survival pattern, which is attributed to therapy resistance and recurrence of the disease. The presence of a rare population, *i.e.,* cancer stem cells (CSCs) within the tumor, are involved in therapy resistance, recurrence, and distant metastasis that results in poor survival patterns. Therapeutic agents targeting CSCs have been in clinical trials, although they are unable to reach into therapy stage which is due to their failure in trials. A more detailed understanding of the CSCs is essential for identifying efficient targets. Molecular signaling pathways, which are differentially regulated in the CSCs, are one of the promising targets to manipulate the CSCs that would provide an improved outcome. In this review, we summarize the current understanding of molecular signaling associated with the maintenance and regulation of CSCs in tongue squamous cell carcinoma in order to emphasize the need of the hour to get a deeper understanding to unravel novel targets.

**Key Words:** Head and neck squamous cell carcinoma; Cancer stem cells; Signaling; Tongue squamous cell carcinoma

**©The** **Author(s) 2023.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**: Joshi P, Waghmare S. Molecular signaling in cancer stem cells of tongue squamous cell carcinoma: therapeutic implications and challenges. *World J Stem Cells* 2023; 15(5): 438-452

**URL**: https://www.wjgnet.com/1948-0210/full/v15/i5/438.htm

**DOI**: https://dx.doi.org/10.4252/wjsc.v15.i5.438

**Core Tip:** Tongue squamous cell carcinoma is one of the most common and aggressive oral cavity carcinomas, particularly among the Indian population. Despite various treatment strategies employed, the survival rates of the patients remain poor. A rare population *i.e.*, cancer stem cells (CSCs), plays an important role in resistance, recurrence as well as metastasis which are factors responsible for the poor survival outcome. In this review, we discuss the recent findings regarding cell signaling pathways and markers associated with the CSCs and the need to gain a deeper understanding on the properties of the CSCs.

**INTRODUCTION**

Global cancer statistics by GLOBOCAN in 2020 showed that 2.0% of new cancer cases reported worldwide were lip and oral cavity cancers, while 1.8% of the total cancer-related deaths were of lip and oral cavity cancers. Lip and oral cavity cancers are the most commonly diagnosed cancers that are responsible for most cancer-related deaths in India[1]. Most cases of oral squamous cell carcinomas (OSCCs) are presented at advanced stages, *i.e.*, stages III or IV [tumor-node-metastasis (TNM) staging], where the 5-year survival of the patients is less than 50%. Further, 40% of the oral carcinomas are presented as tongue carcinomas[2].

Head and neck squamous cell carcinomas (HNSCCs) are carcinomas of the oral cavity, nasopharynx, oropharynx, larynx, and hypopharynx[3]. The oral cavity carcinomas comprise the anterior 2/3rd of the tongue, buccal mucosa, retromolar trigone, lower and upper alveolar ridge, hard palate, and floor of the mouth[3].

The poor survival observed in HNSCCs is primarily attributed to loco-regional/ distant metastasis and therapy resistance. Therefore, understanding the molecular mechanism underlying these properties of tumors has become very crucial. Current treatments for HNSCCs include surgery, chemo- radiotherapy, and targeted therapy.

The first evidence of cancer stem cells (CSCs) was observed in acute myeloid leukemia[4], where it was reported that only 10000 cells expressing CD34+/CD38- could give rise to leukemia in non-obese diabetic-severe combined immunodeficient (NOD-SCID) mice. These cells possess high tumorigenic potential, which are termed as CSCs. CSCs exhibit stem cell-like properties such as self-renewal, slow cycling, and the ability to divide and differentiate into various sub-populations[5]. Further, CSCs were isolated from solid tumors such as breast cancer, HNSCCs, colorectal cancer, ovarian cancer, lung cancer, *etc.*[5].

Owing to their unique properties, these CSCs escape the current treatment regimes, thereby adversely affecting patient survival. Therefore, to design an effective treatment regime in order to achieve better efficiency and treatment outcome, it is crucial to understand the molecular mechanism involved in maintaining these CSCs within the tumor. In this review, we focus on the tongue squamous cell carcinoma (TSCC) and have summarized the known molecular markers of CSCs, molecular signaling involved in the regulation of CSCs, the inhibitors used in clinics for treatment, and the ones that are in clinical trials.

**CSC MARKERS FOR TSCC**

***CD44 and variants***

CD44 is a single-chain proteoglycan transmembrane glycoprotein expressed on human embryonic stem cells at the developmental stages of cell types such as bone marrow and connective tissue. CD44 interacts with molecules such as hyaluronic acid (HA), collagen, osteopontin, fibronectin, chondroitin and serglycin/sulfated proteoglycan. CD44 has variant isoforms such as CD44, CD44s, CD44v3, CD44v6, CD44v8-10[6] with HA as the most specific ligand for CD44 and its isoforms[6].

The first report of isolation and characterization of CSCs from HNSCC showed that 5000 CD44+/Lin- cells gave rise to *in vivo* tumors in NOD-SCID mice[7]. CD44 expression is co-related with the expression of known stem cell marker BMI-1 in HNSCC cells.

Recently, CD44v3 is reported to be overexpressed in HNSCC tumors as compared to the cut margin. Transfection of CD44v3 in the HNSCC cells increases cell migration[8]. Tumor cell growth, migration, matrix metalloproteinase activity, and lymph node metastasis in patients are associated with CD44v3 overexpression in HNSCC cells[9]. Decreased expression of CD44v9 co-relates with poor overall survival (OS) in TSCC[10]. Overexpression of CD44 co-relates with tumor invasiveness and epithelial-mesenchymal transition (EMT). Expression of CD44 in invasive margins of OSCC was associated with samples showing poor histopathological differentiation, high tumor budding activity, and single-cell invasion[11]. Further, increased expression of CD44, together with increased expression of NANOG was associated with poor survival in HNSCC patients as compared to those showing low expression of CD44 and NANOG[12].

Cells overexpressing CD44 (CD44+) showed self-renewal property with high tumorigenic potential, metastasis, and chemo-resistance. Therefore, CD44+ cells in HNSCC tumors are considered as CSC-rich population. CD44, paired with the overexpression of other stem cell markers, such as aldehyde dehydrogenase (ALDH) and CD133, are being used for the isolation of CSCs from HNSCC tumors[13]. In TSCC, CD44+/CD133+ cells showed stem cell-like properties such as high proliferation, invasion, and migration with high tumorigenicity[13].

There have been recent reports linking CD44+ cells in HNSCC tumors to early angiogenesis[14], lymph node metastasis[15], and occult metastasis[16]. Moreover, overexpression of CD44 in adjacent normal epithelia of TSCC co-related with clinical stage and nodal metastasis in patients[17]. CD44 mRNA expression did not show any co-relation with age, sex, smoking history, size of the tumor, or 5-year survival rate[18].

***ALDH***

ALDH is an enzyme superfamily which converts aldehydes to carboxylic acids that are involved in drug resistance and detoxification. The human ALDH1A subfamily is involved in the retinoic acid pathway, which regulates gene expression and cell development in both normal and cancer cells. The enzymes belonging to ALDH1A subfamily viz., ALDH1A1, ALDH1A2, and ALDH1A3 are located in the cytosol that catalyze the irreversible conversion of retinaldehyde to retinoic acid.

Amongst the ALDH1A subfamily, ALDH1A1 is overexpressed in the CSCs of HNSCC. Overexpression of ALDH has co-related with overexpression of other stem cell markers such as OCT-3/4, NANOG, STELLA, SNAIL, and BMI-1 in HNSCC. ALDHhigh cells have also been shown to have increased *in vitro* sphere formation ability and *in vivo* tumorigenesis ability[19,20]. Higher expression of ALDH also co-related with poor patient survival. Importantly, 500 ALDHhigh cells isolated from HNSCC tumors showed a higher tumorigenic potential upon *in vivo* serial transplantations as compared to ALDHlow cells[21]. High expression of ALDH1A1 in oropharyngeal carcinoma co-related with poor differentiation in tumors and poor OS patterns in patients[22]. ALDHhigh TSCC cells showed serum independency and a higher ability to form tumorospheres than ALDHlow cells. ALDHhigh cells also exhibited overexpression of stem cell-related genes such as NOTCH2[23]. ALDH1A1 expression was directly co-related with OS and lymph node metastasis in HNSCC[24]. The study showed a co-relation of ALDH1A1 expression with TWIST1 expression in primary tumor tissues and lymph node metastases. Recent reports have demonstrated the involvement of ALDH isoforms in cisplatin resistance in HNSCC. Treating cells with ALDH inhibitors showed decreased cell viability and reduced tumor burden *in vivo* when given in combination with cisplatin as compared to only cisplatin treatment. This study also showed that treating cells with the ALDH3A1 activator along with cisplatin increased cell survival[25]. Overexpression of ALDH1A1 in HNSCC tissues co-relates with poor survival as compared to low ALDH1A1 expression[26]. Additionally, the expression of ALDH1 increased from epithelial dysplasia to oral carcinoma, that co-related with poor survival rates in OSCC patients[27]. In addition, low ALDH1A1 in the HNSCC patients showed significantly better OS as compared to high ALDH1A1 expression[25].

***CD133***

CD133/AC133/prominin-1 is a 97 kDa pentaspan transmembrane glycoprotein encoded by the prominin 1 (*PROM1*) gene. CD133 protein has an intracellular C-terminal domain, an extracellular N-terminal domain, and five transmembrane segments[28].

Spheroids obtained from HNSCC patient tumor cells showed higher CD133 expression than normal epithelial cells[29]. High expression of CD133 with high expression of CD44 and CD117 was observed as marker of CSCs in OSCC cells[30]. TSCC cells overexpressing CD133 showed a higher *in vitro* and *in vivo* tumorigenicity as compared to cells with low expression of CD133[31]. Recent reports showed that CD133+ OSCC cells exhibit properties such as self-renewal, drug resistance, higher tumorigenic potential, and higher growth rate as compared to CD133- cells. Further, increased expression of stem cell markers such as NANOG, OCT4, SOX2, and ALDH1A1 in CD133+ cells suggested that CD133 is a potential CSC marker for OSCC CSCs[32]. TSCC-derived spheroids were reported to overexpress CD133[33].

***Other markers***

Stemness markers such as OCT-3/4, NANOG, SOX2, KLF-4, and BMI-1 have been associated with characteristics such as self-renewal, pluripotency, and development of embryonic stem cells are overexpressed in CSCs in TSCCs.

Invasive TSCC cells overexpressing CD44 and SOX9 showed a higher expression of SOX2 and OCT-4[34]. SOX2 overexpression in TSCC tissues co-related with poor OS in patients[35]. In addition, SOX2 overexpression co-related with tumor size, cell differentiation, nodal metastasis, and clinical TNM stage. In TSCC cells, the knockdown of SOX2 showed a decrease in cell proliferation, cell migration and invasion, and colony forming, which was reversed with overexpression of SOX2[36]. Moreover, an increased SOX2 expression was associated with poor OS, disease-specific survival, and disease-free survival (DFS) in TSCC[37]. Downregulation of SOX2 by MTA-3 was reported to repress CSC properties and tumor growth in TSCCs, and patients exhibiting MTA3low/SOX2high showed the worst prognosis[38]. Additionally, SOX2 regulated HEY1, which in turn regulates NOTCH4 expression, followed by increased EMT in HNSCC cells[39].

The expression of both OCT-3/4 and NANOG was high in side population cells that co-related with distant metastasis[40]. Also, high OCT-4 expression in TSCC samples and NANOG in adjacent cut margin tissues have been reported as indicators of lymph node metastasis and worse prognosis[12]. Furthermore, TSCC showed an association between BMI-1 overexpression and increased proliferation, nodal metastasis, and decreased OS in patients. Further, knocking down BMI-1 in TSCC cells showed a reduction in cell proliferation and migration, increased cell apoptosis, senescence, and cisplatin sensitivity[41]. Ectopic overexpression of BMI-1 increased susceptibility of tongue carcinogenesis after exposure to 4-nitroquinoline-1-oxide in mice. The ectopic expression of BMI-1 was shown to regulate the pathways such as mTOR signaling, EIF2 signaling, and p70S6K signaling[42]. Additionally, high expression of OCT4 and BMI-1, along with ALDH1, co-related with poor survival in OSCC patients[27].

The *TRIM* (tripartite motif) gene family have ubiquitin ligase function that plays an important role in various human diseases such as muscular dystrophies and atrophies and HIV infections *etc.*[43]. A recent report showed that overexpression of TRIM14 induces CSC-like properties with an increased sphere formation ability and cisplatin resistance in TSCC cells. Further, on inhibition of TRIM14 by miR-15b, these characteristics were reversed, implying that TRIM14 might play an important role in the maintenance of these properties[44].

**MOLECULAR SIGNALING**

***The Wnt pathway***

The Wnt signaling consists of the Canonical (involving β-catenin) and non-canonical pathways. Canonical Wnt signaling initiates when Wnt ligand binds to FRZ receptor and low-density LRP5/6 co-receptors. In the absence of the Wnt ligand, a complex of Axin, APC, GSK3, and CK1 phosphorylates β-catenin, leading to ubiquitination and subsequent proteasomal degradation of β-catenin. When present, Wnt ligand binds to FRZ receptor leading to FRZ-induced LRP5/6 phosphorylation followed by activation of the scaffold protein DVL. Activated DVL recruits Axin to receptors, which then inhibits the phosphorylation of β-catenin. Subsequently, β-catenin translocates into the nucleus promoting the transcription of Wnt target genes by interacting with T cell-specific factor/lymphoid enhancer-binding factor. Proper functioning of the Wnt signaling pathway is important for embryonic development and self-renewal of normal stem cells[45]. Deregulated Wnt signaling is involved in the development of various cancers such as colorectal cancer, epidermal cancer[46], hepatocellular carcinoma, breast cancer, glioma, *etc.*[47].

Recent studies showed that the suppression of the Wnt signaling inhibits the progression of OSCC. Micro RNAs such as miR-29a[48], miR-638[49], miR-106a\*[50], *etc.,* have been shown to suppress tumor progression by regulating the Wnt signaling. The miR-638 and miR-106a\* regulate Wnt through downregulating oncogenes PLD1 and MeCP2, while miR-29a caused reduction in β catenin levels. In addition, chemical compounds such as quercetin (bioactive flavonoid) and niclosamide (anthelminthic) were reported to inhibit tumor progression by affecting the Wnt signaling in OSCC. Quercetin induced miR-22 expression, thereby inhibiting the Wnt1/β catenin axis[51], while Niclosamide downregulated the expression of β-catenin, DVL2, phosphorylated GSK3β, and Cyclin D1[52]. SOX8 was shown to regulate chemo-resistance and EMT in TSCC cells by activating the Wnt pathway suggesting that it might play a crucial role in the maintenance of tongue CSCs[53]. Furthermore, the spheroid forming ability and expression of CSC markers (CD44 and ALDH) was negatively impacted in the presence of the Wnt antagonist sFRP4 in tongue carcinoma cells. In presence of the Wnt ligand, WNT3a, these properties were reverted[54]. The Wnt on and off pathway and its role in TSCC is shown in (Figure 1).

***The Hedgehog pathway***

The Hedgehog pathway has three different types of ligand proteins in mammals such as Sonic-Hedgehog (SHH), Indian-Hedgehog, and Desert-Hedgehog. The ligand binds to the receptor PTCH1 and removes the inhibition on the transmembrane protein Smoothened (SMO). This further leads to SMO accumulation in the cytoplasm. Subsequently, the translocation of glioma-associated oncogene (Gli) proteins into the nucleus initiates the transcription of target genes that are involved in intercellular communication, organogenesis, regeneration, and homeostasis[55].

Hedgehog pathway activation promotes angiogenesis in OSCC. Overexpression of SHH ligand in human TSCC and expression of PTCH1, Gli1, and Gli2 proteins in microvascular cells have been observed in the tumor invasive front[56]. The involvement of Hedgehog pathway has been shown in angiogenesis by macrophages and endothelial cells[57]. Hedgehog and TGFβ signaling are involved in bone invasion and destruction. Gli2 expression is associated with bone invasion. Silencing of Gli2 showed a reduction in invasiveness in orthotopic mice models[58]. Gli3 knockdown in TSCC cells have resulted in the downregulation of the CSC markers such as CD44, OCT-4, and BMI-1 genes and a reduction in CSCs[59]. Further, increased expression of Gli1 has been shown in spheroid forming cells in TSCC cell line[60]. The Hedgehog pathway and its role in TSCC have been shown along with inhibitors in clinical trials for various cancers except for HNSCC (Figure 2).

***The Notch pathway***

The Notch pathway has four receptors such as NOTCH 1, NOTCH 2, NOTCH 3, and NOTCH 4. The ligands are of two types, viz. Delta-like ligands (DLL1, DLL3 and DLL4) and Jagged ligands (JAG1 and JAG2). Notch pathway also involves proteolysis by metalloprotease, tumor necrosis factor-α-converting enzyme (TACE), and γ-secretase. The binding of the ligand to the receptor releases the extracellular domain by TACE activity, which then binds to the receptor on an adjacent cell, while the intracellular domain is cleaved by γ-secretase activity that further gets translocated into the nucleus, which acts like a transcriptional factor for the activation of the target genes (HES family, HEY, NF-κB, VEGF, and c-MYC)[61].

Notch signaling has been shown to induce EMT in OSCC cells. Activation of Notch signaling is directly co-related with the expression of markers such as E-cadherin and Vimentin and increased invasiveness of OSCC cells[62,63]. Decreasing NOTCH1 in the TSCC cells showed a reduction in the invasiveness of the cells and decreased expression of MMP-2 and MMP-9 (associated with metastasis and invasion) in TSCC[64]. Additionally, activation of the notch intracellular domain in TSCC cell line co-related with stemness characteristics such as spheroid formation and expression of stemness markers viz. OCT4, SOX2 and CD44. The knockdown of NOTCH1 co-related with chemo-sensitization and loss of spheroid-forming ability. Further, high expression of NOTCH1 showed a significantly poor OS as well as DFS in HNSCC patients[65]. Further, NOTCH4 expression promoted cell-cycle dysregulation, cell proliferation, drug resistance, and inhibition of apoptosis. Elevated expression of NOTCH4 along with HEY1 co-related with OCT4, SOX2, and CD44 overexpression that showed increased migration and invasion in TSCC cells[66]. Recently, it was reported that a STAT3-activated long non-coding RNA, hepatocyte nuclear factor 1 homeobox A antisense RNA 1, promoted tumorigenesis by activating the Notch pathway in OSCC cells[67]. Further, high expression of NOTCH1 and JAG1 have been shown to be predictors of poor OS as well as DFS in oral carcinoma patients[68]. The notch signaling pathway and its role in TSCC is shown in (Figure 3).

***The HGF/c-MET pathway***

The HGF/c-MET pathway is involved in tumorigenesis in various cancers such as HNSCC, non-small cell lung cancer, hepatocellular carcinoma, ovarian cancer, bladder cancer, cervical cancer, *etc.*[69]. The binding of ligand HGF to the kinase receptor c-MET leads to the dimerization of two subunits. The dimerization results in the auto-phosphorylation of tyrosine residues in the cytoplasmic domain of the receptor, which then creates a docking site for various adaptor proteins that regulate pathways such as PI3K/AKT pathway and Wnt pathway[69].

HGF treatment has been shown to increase the expression of CSC markers and sphere forming ability of HNSCC cells, which were decreased upon c-MET knockdown. The transcriptional level of c-MET was higher in cells with high ALDH activity (one of the HNSCC CSC markers). Moreover, c-MET knockdown in the HNSCC stem-like cells resulted in better survival in *in vivo* orthotopic tongue xenograft models[70].

Significant co-relation has been observed in TSCC between the c-MET expression and tumor stage, nodal status, clinical stage, locoregional recurrence, and distant metastasis. In addition, high expression of c-MET and autocrine motility factor receptor (AMFR) was associated with worse DFS. The study suggested that c-MET and AMFR expression can be potent prognosis marker that targets to decrease metastasis in OSCC[71]. Immunostaining for the c-MET showed a significant co-relation with lymph node metastasis, recurrence, and pathological stage of TSCC[72]. High c-MET expression was co-related with lymph node metastasis, greater depth of invasion, decreased patient survival, increased invasion & migration in *in vitro* and subcutaneous *in vivo* mice model injected with TSCC cells[73]. Further, the knockdown of c-MET has shown to reduce cervical lymph node metastasis and improve survival patterns in *in vivo* models[74]. Overexpression of c-MET was shown to co-relate with occult metastasis in TSCC[75]. The HGF/c-MET pathway and its role in TSCC is shown along with inhibitor in clinical trials for various cancers except for HNSCC (Figure 4).

***Other pathways***

The transcription factor Nrf2 has been shown to induce the expression of genes involved in cellular antioxidant and anti-inflammatory responses. Normally, Nrf2 is located in the cytoplasm. Upon activation, it translocates to the nucleus, forming heterodimers with proteins such as c-JUN and small musculoaponeurotic fibrosarcoma protein that bind to antioxidant response element, which regulate the expression of around 200 genes that regulate anti-inflammatory and antioxidant response. Nrf2 is involved in the regulation of mitochondrial biogenesis pathways[76]. A compound named Plumbagin is shown to suppress EMT and stemness characteristics by regulating redox homeostasis and inducing reactive oxygen species (ROS) generation within the cell by suppressing the Nrf2-regulated pathways[77].

The Hippo/transcriptional coactivator with PDZ-binding (TAZ) signaling pathway is also involved in the regulation of properties such as cell proliferation, apoptosis, invasion, migration *etc.* in TSCC. When the pathway is off, the Yes-associated protein (YAP) and TAZ motif translocate to the nucleus, thereby inducing the transcription of various genes by binding to the TEA domain family proteins and other transcription factors. LATS1 is activated by MST1 with Salvador through phosphorylation, which then phosphorylates the YAP/TAZ, retaining it in the cytoplasm, which then binds to 14-3-3 and gets degraded[78]. Factors such as HIF-1α[79] and epigallocatechin-3-gallate[80] affect the Hippo pathway to modulate proliferation, apoptosis, invasion, and migration in TSCC cells.

Approximately 90% HNSCCs overexpress the EGFR pathway[81]. The EGFR is a receptor tyrosine kinase of the ErbB family. The ligands of the EGFR are EGF, heparin-binding EGF, and TGFα. Upon receptor-ligand binding, the inactive monomer of the receptor dimerizes, either with another monomer of EGFR forming a homodimer or with another ErbB family receptor forming a heterodimer. This active dimer then auto-phosphorylates the C-terminal domain of the receptor providing a docking site for the phospho-tyrosine binding domain and Src homology 2 domain resulting in the activation of several signaling pathways such as MAPK, PI3K/Akt pathway, and phospholipase Cγ pathways[82]. Stimulation of OSCC cells by EGF showed an induction of EMT in the cells, which revealed morphological changes with the downregulation of E-cadherin and the upregulation of vimentin in the cells. In addition, stimulated cells showed enrichment of stem-like population (CD44+/CD24-) with an increase in CSC markers such as ALDH1 and BMI-1, suggesting that EGF may be responsible to induce CSC properties in OSCCs[83].

Ephrin (EPH) receptors and their ligands play important roles in controlling the actin cytoskeleton and cellular responses, including attraction/repulsion, migration, and cell positioning during developmental stages[84]. Recent report has shown regulation of the expression of stemness markers by EPHA10. EPHA10 and its ligand EFNA4 increased cell migration, sphere formation, and expression of markers such as SNAIL, NANOG, and OCT4 in OSCC cells. It was also reported that high mRNA levels of EFNA4 with NANOG or OCT4 co-related with poor survival patterns in OSCC patients[85].

**CURRENT TREATMENT REGIME**

The current treatment regime for HNSCCs is dependent on the TNM staging of the carcinoma based on T (tumor size considering the depth of invasion), N (nodal metastasis considering extranodal extension or ENE), and M (presence of distant metastasis)[86]. For early stage of cancer, single modality treatment, in which mostly surgery, is preferred. With the progression of disease manifested either through larger tumor dimensions or nodal metastasis, multimodality in treatment is employed, wherein surgery is followed by adjuvant chemotherapy or radiotherapy. In case of distant metastasis, where surgical intervention is difficult, chemotherapy is the preferred choice. Further, administration of adjuvant chemo or radiation therapy following surgery is shown to exhibit better patient survival[87]. Chemotherapeutic agents commonly administered are cisplatin, carboplatin, docetaxel, 5-fluorouracil, methotrexate, and paclitaxel. Radiotherapy is also employed in cycles of 1.8-2 Gy/day with a total dose of 66-72 Gy[88]. Targeted therapies, specifically acting on certain upregulated pathways, such as EGFR, are administered. For example, cetuximab targets the EGFR pathway in HNSCC patients or anti-PD1 agents for immunotherapy in HNSCC. Agents such as pembrolizumab and nivolumab, which target PD-1, have shown promising results in clinical trials[87]. Although, recent reports highlighted that owing to heterogeneity in PD-L1 expression throughout tumors and utilization of different methods and antibodies, there might arise errors in immuno-histochemical assessment of PD-L1 prior to therapy decisions[89-92]. In the course of currently existing assessment methods across various cancers, Marletta *et al*[91] observed that in HNSCC, the registration trial utilized the 22C3 clone (Dako) on Agilent autostainer link 48 while the European Medicines Agency granted administration of immunotherapy regardless of antibody, and the instrument used. The reports emphasized on the establishment of a standardized uniform protocol considering the heterogeneity of expression as well as the antibodies and platforms used for the assessment of PD-L1 before deciding whether immunotherapy should be administered to the patients[89-92].

Recently, a clinical trial consisting of 13 TSCC patients showed that immunotherapy of cytokine-induced killer cells after chemotherapy helped in the reversion of immunosuppression caused during chemotherapy and surgery. Twelve out of thirteen patients survived for more than 90 mo post-therapy. No immune system related toxicities were reported in the surviving patients. No other side effects of the treatment were observed except complaints of aphthous ulcers by two patients[93]. This showed that multiple modality treatments might improve the survival and quality of life of the patients. However, for further improvement in treatment, more targets specific to CSCs need to be explored.

There have been few clinical trials worldwide as well as those involving Indian institutes for newer molecules targeting EGFR pathway, immune checkpoints, PD-L1, cyclin-dependent kinases, *etc.,* as single treatment agent or in combination with other chemotherapeutic agents/radiation in HNSCC (Table 1). However, these trials are still in the early phases and do not particularly target CSCs. Therefore, further detailed study is essential in finding newer targets specific to CSCs in HNSCC.

**CONCLUSION**

The CSC population plays an important role in therapy resistance, recurrence, and metastasis. These factors adversely affect patients’ survival. In spite of several years of research, most of the treatment regimes employed currently target the tumor bulk. CSCs possess self-renewing property, slow cycling, aberrant cell signaling, dynamic ABC transporter system, DNA repair mechanism, epigenetic modifications, and metabolic regulation, *etc.*, which enable CSCs to escape this therapy and thereby play an important role in recurrence, therapy resistance, and loco-regional/distant metastasis.

A better understanding of the aberrant signaling pathways involved in poor prognosis and maintenance of the CSC population would be more effective in improving treatment outcome. Such an understanding would also be important in the prognosis, prediction, and designing of treatment regime that not only reduce the bulk of the tumor but also effectively eliminate the CSC population thereby improving patient survival.

Molecules specifically targeting signaling pathways that regulate the CSC population administered in combination with conventional therapy or as a single treatment modality need to be studied in TSCC. Uncovering the signaling pathways for CSCs, and targeting them would enable better clinical outcomes.

**ACKNOWLEDGEMENTS**

Joshi P is supported by ACTREC PhD fellowship. The work was funded by TMC-IRB (3542) and ACTREC annual funds.

**REFERENCES**

1 **Sung H**, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2021; **71**: 209-249 [PMID: 33538338 DOI: 10.3322/caac.21660]

2 **Rivera C**. Essentials of oral cancer. *Int J Clin Exp Pathol* 2015; **8**: 11884-11894 [PMID: 26617944]

3 **Chin D**, Boyle GM, Porceddu S, Theile DR, Parsons PG, Coman WB. Head and neck cancer: past, present and future. *Expert Rev Anticancer Ther* 2006; **6**: 1111-1118 [PMID: 16831082 DOI: 10.1586/14737140.6.7.1111]

4 **Bonnet D**, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. *Nat Med* 1997; **3**: 730-737 [PMID: 9212098 DOI: 10.1038/nm0797-730]

5 **Batlle E**, Clevers H. Cancer stem cells revisited. *Nat Med* 2017; **23**: 1124-1134 [PMID: 28985214 DOI: 10.1038/nm.4409]

6 **Chen C**, Zhao S, Karnad A, Freeman JW. The biology and role of CD44 in cancer progression: therapeutic implications. *J Hematol Oncol* 2018; **11**: 64 [PMID: 29747682 DOI: 10.1186/s13045-018-0605-5]

7 **Prince ME**, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. *Proc Natl Acad Sci U S A* 2007; **104**: 973-978 [PMID: 17210912 DOI: 10.1073/pnas.0610117104]

8 **Reategui EP**, de Mayolo AA, Das PM, Astor FC, Singal R, Hamilton KL, Goodwin WJ, Carraway KL, Franzmann EJ. Characterization of CD44v3-containing isoforms in head and neck cancer. *Cancer Biol Ther*2006; **5**: 1163-1168 [PMID: 16855392 DOI: 10.4161/cbt.5.9.3065]

9 **Wang SJ**, Wreesmann VB, Bourguignon LY. Association of CD44 V3-containing isoforms with tumor cell growth, migration, matrix metalloproteinase expression, and lymph node metastasis in head and neck cancer. *Head Neck* 2007; **29**: 550-558 [PMID: 17252589 DOI: 10.1002/hed.20544]

10 **Sato S**, Miyauchi M, Kato M, Kitajima S, Kitagawa S, Hiraoka M, Kudo Y, Ogawa I, Takata T. Upregulated CD44v9 expression inhibits the invasion of oral squamous cell carcinoma cells. *Pathobiology* 2004; **71**: 171-175 [PMID: 15263805 DOI: 10.1159/000078670]

11 **Boxberg M**, Götz C, Haidari S, Dorfner C, Jesinghaus M, Drecoll E, Boskov M, Wolff KD, Weichert W, Haller B, Kolk A. Immunohistochemical expression of CD44 in oral squamous cell carcinoma in relation to histomorphological parameters and clinicopathological factors. *Histopathology* 2018; **73**: 559-572 [PMID: 29468726 DOI: 10.1111/his.13496]

12 **Rodrigues MFSD**, Xavier FCA, Andrade NP, Lopes C, Miguita Luiz L, Sedassari BT, Ibarra AMC, López RVM, Kliemann Schmerling C, Moyses RA, Tajara da Silva EE, Nunes FD. Prognostic implications of CD44, NANOG, OCT4, and BMI1 expression in tongue squamous cell carcinoma. *Head Neck* 2018; **40**: 1759-1773 [PMID: 29607565 DOI: 10.1002/hed.25158]

13 **Sun Y**, Han J, Lu Y, Yang X, Fan M. Biological characteristics of a cell subpopulation in tongue squamous cell carcinoma. *Oral Dis* 2012; **18**: 169-177 [PMID: 22023137 DOI: 10.1111/j.1601-0825.2011.01860.x]

14 **Ludwig N**, Szczepanski MJ, Gluszko A, Szafarowski T, Azambuja JH, Dolg L, Gellrich NC, Kampmann A, Whiteside TL, Zimmerer RM. CD44(+) tumor cells promote early angiogenesis in head and neck squamous cell carcinoma. *Cancer Lett* 2019; **467**: 85-95 [PMID: 31593802 DOI: 10.1016/j.canlet.2019.10.010]

15 **Ortiz RC**, Lopes NM, Amôr NG, Ponce JB, Schmerling CK, Lara VS, Moyses RA, Rodini CO. CD44 and ALDH1 immunoexpression as prognostic indicators of invasion and metastasis in oral squamous cell carcinoma. *J Oral Pathol Med* 2018; **47**: 740-747 [PMID: 29791975 DOI: 10.1111/jop.12734]

16 **Morand GB**, Ikenberg K, Vital DG, Cardona I, Moch H, Stoeckli SJ, Huber GF. Preoperative assessment of CD44-mediated depth of invasion as predictor of occult metastases in early oral squamous cell carcinoma. *Head Neck* 2019; **41**: 950-958 [PMID: 30561155 DOI: 10.1002/hed.25532]

17 **González-Moles MA**, Bravo M, Ruiz-Avila I, Esteban F, Bascones-Martínez A, González-Moles S. Adhesion molecule CD44 expression in non-tumour epithelium adjacent to tongue cancer. *Oral Oncol* 2004; **40**: 281-286 [PMID: 14747059 DOI: 10.1016/j.oraloncology.2003.08.016]

18 **Kaboodkhani R**, Karimi E, Khorsandi Ashtiani MT, Kowkabi S, Firouzifar MR, Yazdani F, Yazdani N. Evaluation of the Correlation between CD44, Tumor Prognosis and the 5-Year Survival Rate in Patients with Oral Tongue SCC. *Iran J Otorhinolaryngol* 2016; **28**: 407-411 [PMID: 28008391]

19 **Wu J**, Mu Q, Thiviyanathan V, Annapragada A, Vigneswaran N. Cancer stem cells are enriched in Fanconi anemia head and neck squamous cell carcinomas. *Int J Oncol* 2014; **45**: 2365-2372 [PMID: 25340704 DOI: 10.3892/ijo.2014.2677]

20 **Yu CC**, Lo WL, Chen YW, Huang PI, Hsu HS, Tseng LM, Hung SC, Kao SY, Chang CJ, Chiou SH. Bmi-1 Regulates Snail Expression and Promotes Metastasis Ability in Head and Neck Squamous Cancer-Derived ALDH1 Positive Cells. *J Oncol* 2011; **2011** [PMID: 20936121 DOI: 10.1155/2011/609259]

21 **Clay MR**, Tabor M, Owen JH, Carey TE, Bradford CR, Wolf GT, Wicha MS, Prince ME. Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. *Head Neck* 2010; **32**: 1195-1201 [PMID: 20073073 DOI: 10.1002/hed.21315]

22 **Qian X**, Coordes A, Kaufmann AM, Albers AE. Expression of aldehyde dehydrogenase family 1 member A1 and high mobility group box 1 in oropharyngeal squamous cell carcinoma in association with survival time. *Oncol Lett* 2016; **12**: 3429-3434 [PMID: 27900016 DOI: 10.3892/ol.2016.5100]

23 **Zou B**, Sun S, Qi X, Ji P. Aldehyde dehydrogenase activity is a cancer stem cell marker of tongue squamous cell carcinoma. *Mol Med Rep* 2012; **5**: 1116-1120 [PMID: 22307065 DOI: 10.3892/mmr.2012.781]

24 **Qian X**, Wagner S, Ma C, Coordes A, Gekeler J, Klussmann JP, Hummel M, Kaufmann AM, Albers AE. Prognostic significance of ALDH1A1-positive cancer stem cells in patients with locally advanced, metastasized head and neck squamous cell carcinoma. *J Cancer Res Clin Oncol* 2014; **140**: 1151-1158 [PMID: 24770634 DOI: 10.1007/s00432-014-1685-4]

25 **Szafarowski T**, Sierdziński J, Ludwig N, Głuszko A, Filipowska A, Szczepański MJ. Assessment of cancer stem cell marker expression in primary head and neck squamous cell carcinoma shows prognostic value for aldehyde dehydrogenase (ALDH1A1). *Eur J Pharmacol* 2020; **867**: 172837 [PMID: 31811857 DOI: 10.1016/j.ejphar.2019.172837]

26 **Kim J**, Shin JH, Chen CH, Cruz L, Farnebo L, Yang J, Borges P, Kang G, Mochly-Rosen D, Sunwoo JB. Targeting aldehyde dehydrogenase activity in head and neck squamous cell carcinoma with a novel small molecule inhibitor. *Oncotarget* 2017; **8**: 52345-52356 [PMID: 28881734 DOI: 10.18632/oncotarget.17017]

27 **Rao RS**, Raju K L, Augustine D, Patil S. Prognostic Significance of ALDH1, Bmi1, and OCT4 Expression in Oral Epithelial Dysplasia and Oral Squamous Cell Carcinoma. *Cancer Control* 2020; **27**: 1073274820904959 [PMID: 32951453 DOI: 10.1177/1073274820904959]

28 **Glumac PM**, LeBeau AM. The role of CD133 in cancer: a concise review. *Clin Transl Med* 2018; **7**: 18 [PMID: 29984391 DOI: 10.1186/s40169-018-0198-1]

29 **Kaseb HO**, Fohrer-Ting H, Lewis DW, Lagasse E, Gollin SM. Identification, expansion and characterization of cancer cells with stem cell properties from head and neck squamous cell carcinomas. *Exp Cell Res* 2016; **348**: 75-86 [PMID: 27619333 DOI: 10.1016/j.yexcr.2016.09.003]

30 **Silva Galbiatti-Dias AL**, Fernandes GMM, Castanhole-Nunes MMU, Hidalgo LF, Nascimento Filho CHV, Kawasaki-Oyama RS, Ferreira LAM, Biselli-Chicote PM, Pavarino ÉC, Goloni-Bertollo EM. Relationship between CD44high/CD133high/CD117high cancer stem cells phenotype and Cetuximab and Paclitaxel treatment response in head and neck cancer cell lines. *Am J Cancer Res* 2018; **8**: 1633-1641 [PMID: 30210931]

31 **Wang K**, Zhou XK, Wu M, Kang FW, Wang ZL, Zhu Y. Role of CD133(+) cells in tongue squamous carcinomas: Characteristics of 'stemness' in vivo and in vitro. *Oncol Lett* 2016; **12**: 863-870 [PMID: 27446361 DOI: 10.3892/ol.2016.4719]

32 **Ma Z**, Zhang C, Liu X, Fang F, Liu S, Liao X, Tao S, Mai H. Characterisation of a subpopulation of CD133(+) cancer stem cells from Chinese patients with oral squamous cell carcinoma. *Sci Rep* 2020; **10**: 8875 [PMID: 32483269 DOI: 10.1038/s41598-020-64947-9]

33 **Shrivastava S**, Steele R, Sowadski M, Crawford SE, Varvares M, Ray RB. Identification of molecular signature of head and neck cancer stem-like cells. *Sci Rep* 2015; **5**: 7819 [PMID: 25588898 DOI: 10.1038/srep07819]

34 **Misuno K**, Liu X, Feng S, Hu S. Quantitative proteomic analysis of sphere-forming stem-like oral cancer cells. *Stem Cell Res Ther* 2013; **4**: 156 [PMID: 24423398 DOI: 10.1186/scrt386]

35 **Huang CF**, Xu XR, Wu TF, Sun ZJ, Zhang WF. Correlation of ALDH1, CD44, OCT4 and SOX2 in tongue squamous cell carcinoma and their association with disease progression and prognosis. *J Oral Pathol Med* 2014; **43**: 492-498 [PMID: 24450601 DOI: 10.1111/jop.12159]

36 **Liu X**, Qiao B, Zhao T, Hu F, Lam AK, Tao Q. Sox2 promotes tumor aggressiveness and epithelial‑mesenchymal transition in tongue squamous cell carcinoma. *Int J Mol Med* 2018; **42**: 1418-1426 [PMID: 29956740 DOI: 10.3892/ijmm.2018.3742]

37 **Du L**, Yang Y, Xiao X, Wang C, Zhang X, Wang L, Zhang X, Li W, Zheng G, Wang S, Dong Z. Sox2 nuclear expression is closely associated with poor prognosis in patients with histologically node-negative oral tongue squamous cell carcinoma. *Oral Oncol* 2011; **47**: 709-713 [PMID: 21689966 DOI: 10.1016/j.oraloncology.2011.05.017]

38 **Habu N**, Imanishi Y, Kameyama K, Shimoda M, Tokumaru Y, Sakamoto K, Fujii R, Shigetomi S, Otsuka K, Sato Y, Watanabe Y, Ozawa H, Tomita T, Fujii M, Ogawa K. Expression of Oct3/4 and Nanog in the head and neck squamous carcinoma cells and its clinical implications for delayed neck metastasis in stage I/II oral tongue squamous cell carcinoma. *BMC Cancer* 2015; **15**: 730 [PMID: 26483189 DOI: 10.1186/s12885-015-1732-9]

39 **Fukusumi T**, Guo TW, Ren S, Haft S, Liu C, Sakai A, Ando M, Saito Y, Sadat S, Califano JA. Reciprocal activation of HEY1 and NOTCH4 under SOX2 control promotes EMT in head and neck squamous cell carcinoma. *Int J Oncol* 2021; **58**: 226-237 [PMID: 33491747 DOI: 10.3892/ijo.2020.5156]

40 **Li Z**, Wang Y, Yuan C, Zhu Y, Qiu J, Zhang W, Qi B, Wu H, Ye J, Jiang H, Yang J, Cheng J. Oncogenic roles of Bmi1 and its therapeutic inhibition by histone deacetylase inhibitor in tongue cancer. *Lab Invest*2014; **94**: 1431-1445 [PMID: 25286028 DOI: 10.1038/labinvest.2014.123]

41 **Yao Z**, Du L, Xu M, Li K, Guo H, Ye G, Zhang D, Coppes RP, Zhang H. MTA3-SOX2 Module Regulates Cancer Stemness and Contributes to Clinical Outcomes of Tongue Carcinoma. *Front Oncol* 2019; **9**: 816 [PMID: 31552166 DOI: 10.3389/fonc.2019.00816]

42 **Kalish JM**, Tang XH, Scognamiglio T, Zhang T, Gudas LJ. Doxycycline-induced exogenous Bmi-1 expression enhances tumor formation in a murine model of oral squamous cell carcinoma. *Cancer Biol Ther*2020; **21**: 400-411 [PMID: 32037955 DOI: 10.1080/15384047.2020.1720485]

43 **Sardiello M**, Cairo S, Fontanella B, Ballabio A, Meroni G. Genomic analysis of the TRIM family reveals two groups of genes with distinct evolutionary properties. *BMC Evol Biol* 2008; **8**: 225 [PMID: 18673550 DOI: 10.1186/1471-2148-8-225]

44 **Wang X**, Guo H, Yao B, Helms J. miR-15b inhibits cancer-initiating cell phenotypes and chemoresistance of cisplatin by targeting TRIM14 in oral tongue squamous cell cancer. *Oncol Rep* 2017; **37**: 2720-2726 [PMID: 28350138 DOI: 10.3892/or.2017.5532]

45 **Li N**, Lu N, Xie C. The Hippo and Wnt signalling pathways: crosstalk during neoplastic progression in gastrointestinal tissue. *FEBS J* 2019; **286**: 3745-3756 [PMID: 31342636 DOI: 10.1111/febs.15017]

46 **Reya T**, Clevers H. Wnt signalling in stem cells and cancer. *Nature* 2005; **434**: 843-850 [PMID: 15829953 DOI: 10.1038/nature03319]

47 **Taciak B**, Pruszynska I, Kiraga L, Bialasek M, Krol M. Wnt signaling pathway in development and cancer. *J Physiol Pharmacol* 2018; **69** [PMID: 29980141 DOI: 10.26402/jpp.2018.2.07]

48 **Huang C**, Wang L, Song H, Wu C. MiR-29a inhibits the progression of oral squamous cell carcinoma by targeting Wnt/β-catenin signalling pathway. *Artif Cells Nanomed Biotechnol* 2019; **47**: 3037-3042 [PMID: 31342798 DOI: 10.1080/21691401.2019.1576712]

49 **Tang KL**, Tang HY, Du Y, Tian T, Xiong SJ. MiR-638 suppresses the progression of oral squamous cell carcinoma through wnt/β-catenin pathway by targeting phospholipase D1. *Artif Cells Nanomed Biotechnol* 2019; **47**: 3278-3285 [PMID: 31379206 DOI: 10.1080/21691401.2019.1647222]

50 **Zhang N**, Wei ZL, Yin J, Zhang L, Wang J, Jin ZL. MiR-106a\* inhibits oral squamous cell carcinoma progression by directly targeting MeCP2 and suppressing the Wnt/β-Catenin signaling pathway. *Am J Transl Res* 2018; **10**: 3542-3554 [PMID: 30662606]

51 **Zhang C**, Hao Y, Sun Y, Liu P. Quercetin suppresses the tumorigenesis of oral squamous cell carcinoma by regulating microRNA-22/WNT1/β-catenin axis. *J Pharmacol Sci* 2019; **140**: 128-136 [PMID: 31257059 DOI: 10.1016/j.jphs.2019.03.005]

52 **Wang LH**, Xu M, Fu LQ, Chen XY, Yang F. The Antihelminthic Niclosamide Inhibits Cancer Stemness, Extracellular Matrix Remodeling, and Metastasis through Dysregulation of the Nuclear β-catenin/c-Myc axis in OSCC. *Sci Rep* 2018; **8**: 12776 [PMID: 30143678 DOI: 10.1038/s41598-018-30692-3]

53 **Xie SL**, Fan S, Zhang SY, Chen WX, Li QX, Pan GK, Zhang HQ, Wang WW, Weng B, Zhang Z, Li JS, Lin ZY. SOX8 regulates cancer stem-like properties and cisplatin-induced EMT in tongue squamous cell carcinoma by acting on the Wnt/β-catenin pathway. *Int J Cancer* 2018; **142**: 1252-1265 [PMID: 29071717 DOI: 10.1002/ijc.31134]

54 **Warrier S**, Bhuvanalakshmi G, Arfuso F, Rajan G, Millward M, Dharmarajan A. Cancer stem-like cells from head and neck cancers are chemosensitized by the Wnt antagonist, sFRP4, by inducing apoptosis, decreasing stemness, drug resistance and epithelial to mesenchymal transition. *Cancer Gene Ther* 2014; **21**: 381-388 [PMID: 25104726 DOI: 10.1038/cgt.2014.42]

55 **Carballo GB**, Honorato JR, de Lopes GPF, Spohr TCLSE. A highlight on Sonic hedgehog pathway. *Cell Commun Signal* 2018; **16**: 11 [PMID: 29558958 DOI: 10.1186/s12964-018-0220-7]

56 **Kuroda H**, Kurio N, Shimo T, Matsumoto K, Masui M, Takabatake K, Okui T, Ibaragi S, Kunisada Y, Obata K, Yoshioka N, Kishimoto K, Nagatsuka H, Sasaki A. Oral Squamous Cell Carcinoma-derived Sonic Hedgehog Promotes Angiogenesis. *Anticancer Res* 2017; **37**: 6731-6737 [PMID: 29187450 DOI: 10.21873/anticanres.12132]

57 **Valverde Lde F**, Pereira Tde A, Dias RB, Guimarães VS, Ramos EA, Santos JN, Gurgel Rocha CA. Macrophages and endothelial cells orchestrate tumor-associated angiogenesis in oral cancer via hedgehog pathway activation. *Tumour Biol* 2016; **37**: 9233-9241 [PMID: 26768620 DOI: 10.1007/s13277-015-4763-6]

58 **Cannonier SA**, Gonzales CB, Ely K, Guelcher SA, Sterling JA. Hedgehog and TGFβ signaling converge on Gli2 to control bony invasion and bone destruction in oral squamous cell carcinoma. *Oncotarget*2016; **7**: 76062-76075 [PMID: 27738315 DOI: 10.18632/oncotarget.12584]

59 **Rodrigues MFSD**, Miguita L, De Andrade NP, Heguedusch D, Rodini CO, Moyses RA, Toporcov TN, Gama RR, Tajara EE, Nunes FD. GLI3 knockdown decreases stemness, cell proliferation and invasion in oral squamous cell carcinoma. *Int J Oncol* 2018; **53**: 2458-2472 [PMID: 30272273 DOI: 10.3892/ijo.2018.4572]

60 **Essid N**, Chambard JC, Elgaaïed AB. Induction of epithelial-mesenchymal transition (EMT) and Gli1 expression in head and neck squamous cell carcinoma (HNSCC) spheroid cultures. *Bosn J Basic Med Sci*2018; **18**: 336-346 [PMID: 30172250 DOI: 10.17305/bjbms.2018.3243]

61 **Xiao YF**, Yong X, Tang B, Qin Y, Zhang JW, Zhang D, Xie R, Yang SM. Notch and Wnt signaling pathway in cancer: Crucial role and potential therapeutic targets (Review). *Int J Oncol* 2016; **48**: 437-449 [PMID: 26648421 DOI: 10.3892/ijo.2015.3280]

62 **Ishida T**, Hijioka H, Kume K, Miyawaki A, Nakamura N. Notch signaling induces EMT in OSCC cell lines in a hypoxic environment. *Oncol Lett* 2013; **6**: 1201-1206 [PMID: 24179495 DOI: 10.3892/ol.2013.1549]

63 **Zhang J**, Zheng G, Zhou L, Li P, Yun M, Shi Q, Wang T, Wu X. Notch signalling induces epithelial‑mesenchymal transition to promote metastasis in oral squamous cell carcinoma. *Int J Mol Med* 2018; **42**: 2276-2284 [PMID: 30015856 DOI: 10.3892/ijmm.2018.3769]

64 **Yu B**, Wei J, Qian X, Lei D, Ma Q, Liu Y. Notch1 signaling pathway participates in cancer invasion by regulating MMPs in lingual squamous cell carcinoma. *Oncol Rep* 2012; **27**: 547-552 [PMID: 21993452 DOI: 10.3892/or.2011.1492]

65 **Lee SH**, Do SI, Lee HJ, Kang HJ, Koo BS, Lim YC. Notch1 signaling contributes to stemness in head and neck squamous cell carcinoma. *Lab Invest* 2016; **96**: 508-516 [PMID: 26927514 DOI: 10.1038/labinvest.2015.163]

66 **Fukusumi T**, Guo TW, Sakai A, Ando M, Ren S, Haft S, Liu C, Amornphimoltham P, Gutkind JS, Califano JA. The NOTCH4-HEY1 Pathway Induces Epithelial-Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma. *Clin Cancer Res* 2018; **24**: 619-633 [PMID: 29146722 DOI: 10.1158/1078-0432.CCR-17-1366]

67 **Liu Z**, Li H, Fan S, Lin H, Lian W. STAT3-induced upregulation of long noncoding RNA HNF1A-AS1 promotes the progression of oral squamous cell carcinoma via activating Notch signaling pathway. *Cancer Biol Ther* 2019; **20**: 444-453 [PMID: 30404566 DOI: 10.1080/15384047.2018.1529119]

68 **Elhendawy HA,** Al-zaharani N, Ehab Z, Soliman N, Ibrahiem AT. Notch1-Jagged1 Signaling Pathway in Oral Squamous Cell Carcinoma : Relation to Tumor Recurrence and Patient Survival. *Open Access Maced J Med Sci* 2022; **10**: 1417-1426 [DOI: 10.3889/oamjms.2022.10200]

69 **Zhang H**, Feng Q, Chen WD, Wang YD. HGF/c-MET: A Promising Therapeutic Target in the Digestive System Cancers. *Int J Mol Sci* 2018; **19** [PMID: 30360560 DOI: 10.3390/ijms19113295]

70 **Lim YC**, Kang HJ, Moon JH. C-Met pathway promotes self-renewal and tumorigenecity of head and neck squamous cell carcinoma stem-like cell. *Oral Oncol* 2014; **50**: 633-639 [PMID: 24835851 DOI: 10.1016/j.oraloncology.2014.04.004]

71 **Endo K**, Shirai A, Furukawa M, Yoshizaki T. Prognostic value of cell motility activation factors in patients with tongue squamous cell carcinoma. *Hum Pathol* 2006; **37**: 1111-1116 [PMID: 16867875 DOI: 10.1016/j.humpath.2006.03.020]

72 **Kim CH**, Koh YW, Han JH, Kim JW, Lee JS, Baek SJ, Hwang HS, Choi EC. c-Met expression as an indicator of survival outcome in patients with oral tongue carcinoma. *Head Neck* 2010; **32**: 1655-1664 [PMID: 20848408 DOI: 10.1002/hed.21383]

73 **Lim YC**, Han JH, Kang HJ, Kim YS, Lee BH, Choi EC, Kim CH. Overexpression of c-Met promotes invasion and metastasis of small oral tongue carcinoma. *Oral Oncol* 2012; **48**: 1114-1119 [PMID: 22704061 DOI: 10.1016/j.oraloncology.2012.05.013]

74 **Tao X**, Hill KS, Gaziova I, Sastry SK, Qui S, Szaniszlo P, Fennewald S, Resto VA, Elferink LA. Silencing Met receptor tyrosine kinase signaling decreased oral tumor growth and increased survival of nude mice. *Oral Oncol* 2014; **50**: 104-112 [PMID: 24268630 DOI: 10.1016/j.oraloncology.2013.10.014]

75 **Shin JH**, Yoon HJ, Kim SM, Lee JH, Myoung H. Analyzing the factors that influence occult metastasis in oral tongue cancer. *J Korean Assoc Oral Maxillofac Surg* 2020; **46**: 99-107 [PMID: 32364349 DOI: 10.5125/jkaoms.2020.46.2.99]

76 **Petri S**, Körner S, Kiaei M. Nrf2/ARE Signaling Pathway: Key Mediator in Oxidative Stress and Potential Therapeutic Target in ALS. *Neurol Res Int* 2012; **2012**: 878030 [PMID: 23050144 DOI: 10.1155/2012/878030]

77 **Pan ST**, Qin Y, Zhou ZW, He ZX, Zhang X, Yang T, Yang YX, Wang D, Zhou SF, Qiu JX. Plumbagin suppresses epithelial to mesenchymal transition and stemness via inhibiting Nrf2-mediated signaling pathway in human tongue squamous cell carcinoma cells. *Drug Des Devel Ther* 2015; **9**: 5511-5551 [PMID: 26491260 DOI: 10.2147/DDDT.S89621]

78 **Ma S**, Meng Z, Chen R, Guan KL. The Hippo Pathway: Biology and Pathophysiology. *Annu Rev Biochem* 2019; **88**: 577-604 [PMID: 30566373 DOI: 10.1146/annurev-biochem-013118-111829]

79 **Chen JY**, Zhang YG, Du JD. HIF-1α restricts proliferation and apoptosis of Tca8113 cells through up regulation of Hippo signaling pathway under hypoxic conditions. *Eur Rev Med Pharmacol Sci* 2018; **22**: 6832-6837 [PMID: 30402847 DOI: 10.26355/eurrev\_201810\_16151]

80 **Li A**, Gu K, Wang Q, Chen X, Fu X, Wang Y, Wen Y. Epigallocatechin-3-gallate affects the proliferation, apoptosis, migration and invasion of tongue squamous cell carcinoma through the hippo-TAZ signaling pathway. *Int J Mol Med* 2018; **42**: 2615-2627 [PMID: 30106116 DOI: 10.3892/ijmm.2018.3818]

81 **Rabinowits G**, Haddad RI. Overcoming resistance to EGFR inhibitor in head and neck cancer: a review of the literature. *Oral Oncol* 2012; **48**: 1085-1089 [PMID: 22840785 DOI: 10.1016/j.oraloncology.2012.06.016]

82 **Rajaram P**, Chandra P, Ticku S, Pallavi BK, Rudresh KB, Mansabdar P. Epidermal growth factor receptor: Role in human cancer. *Indian J Dent Res* 2017; **28**: 687-694 [PMID: 29256471 DOI: 10.4103/ijdr.IJDR\_534\_16]

83 **Xu Q**, Zhang Q, Ishida Y, Hajjar S, Tang X, Shi H, Dang CV, Le AD. EGF induces epithelial-mesenchymal transition and cancer stem-like cell properties in human oral cancer cells via promoting Warburg effect. *Oncotarget* 2017; **8**: 9557-9571 [PMID: 27926487 DOI: 10.18632/oncotarget.13771]

84 **Klein R**. Eph/ephrin signalling during development. *Development* 2012; **139**: 4105-4109 [PMID: 23093422 DOI: 10.1242/dev.074997]

85 **Chen YL**, Yen YC, Jang CW, Wang SH, Huang HT, Chen CH, Hsiao JR, Chang JY, Chen YW. Ephrin A4-ephrin receptor A10 signaling promotes cell migration and spheroid formation by upregulating NANOG expression in oral squamous cell carcinoma cells. *Sci Rep* 2021; **11**: 644 [PMID: 33436772 DOI: 10.1038/s41598-020-80060-3]

86 **Huang SH**, O'Sullivan B. Overview of the 8th Edition TNM Classification for Head and Neck Cancer. *Curr Treat Options Oncol* 2017; **18**: 40 [PMID: 28555375 DOI: 10.1007/s11864-017-0484-y]

87 **Cramer JD**, Burtness B, Le QT, Ferris RL. The changing therapeutic landscape of head and neck cancer. *Nat Rev Clin Oncol* 2019; **16**: 669-683 [PMID: 31189965 DOI: 10.1038/s41571-019-0227-z]

88 **Gharat SA**, Momin M, Bhavsar C. Oral Squamous Cell Carcinoma: Current Treatment Strategies and Nanotechnology-Based Approaches for Prevention and Therapy. *Crit Rev Ther Drug Carrier Syst* 2016; **33**: 363-400 [PMID: 27910740 DOI: 10.1615/CritRevTherDrugCarrierSyst.2016016272]

89 **Girolami I**, Pantanowitz L, Munari E, Martini M, Nocini R, Bisi N, Molteni G, Marchioni D, Ghimenton C, Brunelli M, Eccher A. Prevalence of PD-L1 expression in head and neck squamous precancerous lesions: a systematic review and meta-analysis. *Head Neck* 2020; **42**: 3018-3030 [PMID: 32567746 DOI: 10.1002/hed.26339]

90 **Nocini R**, Vianini M, Girolami I, Calabrese L, Scarpa A, Martini M, Morbini P, Marletta S, Brunelli M, Molteni G, Parwani A, Pantanowitz L, Eccher A. PD-L1 in oral squamous cell carcinoma: A key biomarker from the laboratory to the bedside. *Clin Exp Dent Res* 2022; **8**: 690-698 [PMID: 35593124 DOI: 10.1002/cre2.590]

91 **Marletta S**, Fusco N, Munari E, Luchini C, Cimadamore A, Brunelli M, Querzoli G, Martini M, Vigliar E, Colombari R, Girolami I, Pagni F, Eccher A. Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems. *J Pers Med* 2022; **12** [PMID: 35887569 DOI: 10.3390/jpm12071073]

92 **Paolino G**, Pantanowitz L, Barresi V, Pagni F, Munari E, Moretta L, Brunelli M, Bariani E, Vigliar E, Pisapia P, Malapelle U, Troncone G, Girolami I, Eccher A. PD-L1 evaluation in head and neck squamous cell carcinoma: Insights regarding specimens, heterogeneity and therapy. *Pathol Res Pract* 2021; **226**: 153605 [PMID: 34530257 DOI: 10.1016/j.prp.2021.153605]

93 **Huang X**, Zhang J, Li X, Huang H, Liu Y, Yu M, Zhang Y, Wang H. Rescue of iCIKs transfer from PD-1/PD-L1 immune inhibition in patients with resectable tongue squamous cell carcinoma (TSCC). *Int Immunopharmacol* 2018; **59**: 127-133 [PMID: 29653410 DOI: 10.1016/j.intimp.2018.04.011]

**Footnotes**

**Conflict-of-interest statement:** The authors have no conflicts of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Corresponding Author's Membership in Professional Societies:** International Society for Stem Cell Research.

**Peer-review started:** December 22, 2022

**First decision:** January 31, 2023

**Article in press:** April 7, 2023

**Specialty type:** Cell biology

**Country/Territory of origin:** India

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): B, B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Eccher A, Italy; Horiguchi T, Japan; Jin C, China **S-Editor:** Zhang H **L-Editor:** A **P-Editor:** Zhang H

**Figure Legends**

**图示

描述已自动生成**

**Figure 1 The Wnt signaling pathway and cancer stemness.** In the absence of a Wnt ligand, in the canonical pathway,, a complex of Axin, CK1α, APC, PP2A, and GSK3 (termed destruction complex) phosphorylates β-catenin targeting it for ubiquitinylation, that leads to its proteasomal degradation. When the Wnt ligand binds to the Frizzled receptor and LRP5/6 co-receptor, the destruction complex gets localized to the receptor, preventing the degradation of β-catenin that localizes to the nucleus that further activates transcription of the target genes. It has been reported that miRNAs such as miR-29a, miR-638, and miR-106a\* reduce levels of β-catenin and Wnt ligand. The miR-638 targets PLD1, a generally accepted oncogene, leading to the reduction β-catenin levels[49]. The miR-29a also directly causes a reduction in β-catenin levels in TSCC cell lines[48]. The miRNA miR-106a\* causes a reduction in MeCP2 (a gene expression regulator and oncogene) levels that inhibit the binding of Wnt ligand to the receptor that in turn causes downregulation of the Wnt pathway[50]. Chemical compounds such as Quercetin and Niclosamide downregulate the Wnt signaling pathway. Quercetin causes an increase in levels of miR-22 that in turn inhibits the Wnt1/β-catenin axis[51], while Niclosamide directly binds to DVL2, phosphorylated GSK3β, and Cyclin D1 that reduces levels of β-catenin[52]. Sox8 is shown to activate the Wnt pathway by inducing the expression of Frizzled-7[53].

**图示

描述已自动生成**

**Figure 2 The Hedgehog signaling pathway and cancer stemness.** In the absence of Hedgehog ligand, Patched inhibits smoothened (SMO), leading to the full-length Gli protein that gets phosphorylated by PKA, GSK-3 and CK-1 and converted into Gli repressor through proteolytic digestion. The Gli repressor further inhibits the Hedgehog pathway. When the Hedgehog ligand binds to the Patched receptor, the inhibition on SMO is released, leading to the dissociation of Gli from SUFU and Kif7 that lead to the activation of the Gli protein (Gli A). Further, Gli A translocates to the nucleus that further activates transcription of target genes. Activation of the Hedgehog pathway promotes angiogenesis and invasiveness *in vivo*[57,58]. Downregulation of Gli3 reduces expression of stemness markers such as CD44, OCT-4, and BMI-1 in tongue carcinoma (TSCC) cells[59], while upregulation of Gli1 increases the spheroid formation ability of TSCC cells[60]. IPI-926 and BMS-833923 (XL139) are SMO inhibitors used to therapeutically target the Hedgehog pathway. IPI-926 is a semi-synthetic derivative of cyclopamine, while BMS-833923 (XL139) is a small molecule inhibitor of SMO. Ptch: Patched; SMO: Smoothened; Hh: Hedgehog ligand; Gli FL: Full length glioma associated oncogene; Gli A: Gli activator; Gli R: Gli repressor; IPI-926, BMS-833923 (XL139): Smoothened inhibitors.

**日程表

描述已自动生成**

**Figure 3 The Notch signaling pathway and cancer stemness.** In absence of the Notch ligand, the Notch pathway is in the inactivate state. The binding of ligand to the Notch receptor leads to cleavage by ADAM-family metalloproteases releasing the extracellular domain of the receptor. Further, the receptor is cleaved by γ-secretase leading to the formation of the Notch intracellular domain (NICD), thereby activating it. The NICD then translocates to the nucleus and releases inhibition on the target genes by dissociating the corepressor complex and forms a complex with RBP-J and co-activator complex thereby activating the transcription of target genes. Further, knockdown of Notch-1 expression has been shown to increase chemo-sensitization and decrease the spheroid formation ability of tongue squamous cell carcinoma (TSCC) cells[64]. An increase in Notch-4 levels increases stemness markers such as CD44, SOX2, and OCT-4 in TSCC cells[66]. NICD activation has been shown to increase levels of CD44, OCT-4, and SOX2 in TSCC cells[65]. Activation of the Notch pathway increases the invasiveness in TSCC cells[62,63,66,67]. NICD: Notch intracellular domain.

**图片包含 图示

描述已自动生成**

**Figure 4 The HGF/c-MET signaling pathway and cancer stemness.** In the absence of the HGF ligand, the HGF/c-MET pathway remains inactivated. The binding of the HGF ligand to the c-MET kinase receptor results in the dimerization of two subunits that further leads to auto-phosphorylation of the tyrosine residues in the cytoplasmic domain of the receptor creating a docking site for adaptor proteins, which regulate pathways, such as PI3K, RAS, Wnt, Notch and STAT pathway. Transcriptional levels of c-MET were high in ALDHhigh cells[70]. Activation of c-MET results in an increase in invasiveness and metastasis *in vitro* as well as *in vivo*[73,74]. Ficlatuzumab is a humanized IgG1 monoclonal antibody targeting HGF used to therapeutically target the HGF/c-met pathway. ALDH: Aldehyde dehydrogenase; Ficlatuzumab: HGF/c-MET pathway inhibitor.

**Table 1 Clinical trials currently active for head and neck squamous cell carcinoma**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Region** | **Drug name** | **Target** | **Phase** | **NCT number** |
| Worldwide | Everolimus | Inhibitor of mTOR | I | NCT01637194 |
| Cetuximab | Monoclonal anti-EGFR antibody |
| Bevacizumab (with fluorouracil and hydroxyurea) | Anti VEGF-A antibody | I | NCT00023959 |
| Trastuzumab (with IL-12) | Monoclonal anti-EGFR antibody | I | NCT00004074 |
| Erlotinib | Tyrosine kinase receptor (EGFR) | I, II | NCT00101348 |
| Cetuximab | Monoclonal anti-EGFR antibody |
| With or without bevacizumab | Anti VEGF-A antibody |
| Erlotinib hydrochloride | Tyrosine kinase receptor (EGFR) | I, II | NCT00101348 |
| Cetuximab | Monoclonal anti-EGFR antibody |
| Erlotinib hydrochloride | Tyrosine kinase receptor (EGFR) | I | NCT00397384 |
| Cetuximab | Monoclonal anti-EGFR antibody |
| Zalutumumab (after radiotherapy) | Monoclonal anti-EGFR antibody | III | NCT00496652 |
| Temsirolimus | mTORC1 inhibitor | II | NCT01256385 |
| With or without cetuximab | Monoclonal anti-EGFR antibody |
| Cetuximab | Monoclonal anti-EGFR antibody | II | NCT00939627 |
| Sorafenib tosylate | Tyrosine kinase inhibitor |
| Cetuximab | Monoclonal anti-EGFR antibody | II | NCT01316757 |
| Erlotinib hydrochloride | Tyrosine kinase receptor (EGFR) |
| Varlilumab | Monoclonal anti-CD27 antibody | I, II | NCT02335918 |
| Nivolumab | Monoclonal anti-PD-1 antibody |
| MEDI7247 | Monoclonal anti-ASCT2 antibody conjugated with pyrrolobenzodiazepine dimer | I | NCT03811652 |
| Cetuximab with lenalidomide | Monoclonal anti-EGFR antibody | I | NCT01254617 |
| Durvalumab | Monoclonal antibody that blocks PD-1/PD-L1 interaction | I | NCT03144778 |
| With or without tremelimumab | Monoclonal antibody against CTLA-4 |
| Sitravitinib | Inhibitor of receptor tyrosine kinases | Early phase I | NCT03575598 |
| Nivolumab | Monoclonal anti-PD-1 antibody |
| Nivolumab | Monoclonal anti-PD-1 antibody | I | NCT03229278 |
| Pembrolizumab with trigriluzole | Monoclonal anti-PD-1 antibody |
| BKM120 | PI3K inhibitor | I, II | NCT01816984 |
| Cetuximab | Monoclonal anti-EGFR antibody |
| FATE-NK100 |  | I | NCT03319459 |
| Cetuximab | Monoclonal anti-EGFR antibody |
| Trastuzumab | Monoclonal anti-EGFR antibody |
| Nivolumab with SBRT | Monoclonal anti-PD-1 antibody | II | NCT02684253 |
| BYL719 | PI3K inhibitor | II | NCT03292250 |
| Poziotinib | EGFR inhibitor |
| Nintedanib | Angiokinase inhibitor |
| Abemaciclib | CDK4 and CD6 inhibitor |
| Durvalumab | Monoclonal antibody that blocks PD-1/PD-L1 interaction |
| Tremelimumab | Monoclonal anti-CTLA-4 antibody |
| Nivolumab and tadalafil | Monoclonal anti-PD-1 antibody | Early phase I | NCT03238365 |
| Involving Indian institutes | Gefitinib (Iressa) with cisplatin and radiotherapy | EGFR inhibitor (tyrosine kinase inhibitor) | II | NCT00229723 |
| Lapatinib | EGFR inhibitor (tyrosine kinase inhibitor) | II | NCT00371566 |
| Gefitinib with methotrexate | EGFR inhibitor (tyrosine kinase inhibitor) | III | NCT00206219 |
| P276-00 with EBRT | CDK inhibitor | I, II | NCT00899054 |
| P276-00 | CDK inhibitor | II | NCT00824343 |
| Lapatinib with chemoradiation | EGFR inhibitor (tyrosine kinase inhibitor) | III | NCT00424255 |
| Lapatinib with chemoradiation | EGFR inhibitor (tyrosine kinase inhibitor) | II | NCT00387127 |
| MEDI4736 | Monoclonal antibody blocking interaction between PD-L1 with its receptors | III | NCT02551159 |
| Tremelimumab with chemotherapy | Monoclonal anti-CTLA-4 antibody |

SBRT: Stereotactic radiation therapy.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2023 Baishideng Publishing Group Inc. All rights reserved.**